Aim: The risk of recurrence in breast cancer depends on factors such as treatment but also on the intrinsic subtype. We analyzed the risk factors for local, loco-regional and systemic recurrence, evaluated the differences and analyzed the risk of recurrence for different molecular subtypes. Material and Methods: A total of 3054 breast cancer patients who underwent surgery followed by adjuvant treatment at HSK hospital or Essen Mitte Hospital between 1998 and 2011 were analyzed. Based on immunohistochemical parameters, cancers were divided into the following subgroups: luminal A, luminal B (HER2-), luminal B (HER2+), HER2+ and TNBC (triple negative breast cancer). Results: 67 % of tumors were classified as luminal A, 13 % as luminal B (HER2-), 6% as luminal B (HER2+), 3 % as HER2+ and 11% as TNBC. After a median follow-up time of 6.6 years there were 100 local (3.3 %), 32 loco-regional (1 %) and 248 distant recurrences (8 %). Five-year recurrencefree survival for the overall patient collective was 92 %. On multivariate analysis, positive nodal status, TNBC subtype and absence of radiation therapy were found to be independent risk factors for all forms of recurrence. Age < 50 years, tumor size, luminal B (HER2-) subtype and breast-conserving therapy were additional risk factors for local recurrence. Compared to the luminal A subtype, the risk of systemic recurrence was higher for all other subtypes; additional risk factors for systemic recurrence were lymphatic invasion, absence of systemic therapy and mastectomy. Conclusion: Overall, the risk of local and loco-regional recurrence was low. In addition to nodal status, subgroup classification was found to be an important factor affecting the risk of recurrence.
Prognostic Factors for Local, Loco-regional and Systemic Recurrence in Early-stage Breast Cancer Introduction ! With around 75 000 new cases every year, breast cancer is by far the most common cancer for women in Germany [1] . As part of national and international certification procedures, German breast centers have been instructed to develop quality indicators for the diagnosis, treatment and follow-up of breast cancer patients. The recommendations of the German Cancer Society (DKG) and the EUSOMA (European Society of Mastology) postulate that the rate for breast-conserving surgery (BCS) should be 70-90 % for T1 stage tumors [2] and at least 70 % for tumors < 3 cm [3] . However, there is also the need to comply with another quality criteria, namely, that the maximum local recurrence rate after BCS does not exceed 15 % and the maximum recurrence rate after mastectomy does not exceed 10% over a period of 10 years [4]. Rates of radical loco-regional surgery have decreased significantly in the last 30 years, starting with the evidence that BCS combined with radiation of the residual breast tissue is at least equal to mastectomy in terms of local recurrence and overall survival [5] [6] [7] [8] [9] . Determination of nodal status is required for staging, with nodal status remaining a very important prognostic parameter. However, recently there has also been an important change in the surgical radicality of this staging procedure. Conventional complete axillary lymph node dissection (ALND) which has been established since decades has been replaced by less invasive sentinel lymph node biopsy (SNB) procedures in clinically node-negative patients, after it was shown that SNB is a safe alternative and is associated with significantly lower morbidity [10] [11] [12] [13] . Gene expression analysis provides important information about the tumor biology of the breast cancer. Five molecular subtype groups have been identified which provide more subtle information about the risk of recurrence and overall patient survival [14, 15] . However, for reasons of time and because of the higher costs involved, gene expression analysis is not carried out as a standard procedure in daily clinical routine. Nevertheless, routine determination of specific pathological parameters such as hormone receptor and HER2 status, tumor grade and Ki67 expression can be used for an approximate grouping of the cancer into subtypes which have been found to correlate well with gene expression-based grouping into subtypes [16, 17] . Several studies have reported a correlation between the classification into subgroups based on pathological investigation and clinical outcomes [18] [19] [20] [21] [22] [23] . Several commercially available test methods based on the expression profiles of selected genes are used to determine the therapy of hormone receptor-positive cancers [24] and provide the most individualized treatment plans possible [25] . The aim of this study was to evaluate the data of an unselected patient population from two breast centers (HSK Wiesbaden hospital and Essen-Mitte hospital) accredited by the European Society of Breast Cancer Specialists (EUSOMA) with regard to the prognostic factors for local, loco-regional and systemic recurrence, to identify potential differences and discuss these differences in terms of international benchmarking. The data was also used to examine patterns of recurrence in the different clinical subgroups.
Material and Methods

!
Patient population and data acquisition
In this retrospective analysis, the data of patients with a primary diagnosis of early-stage invasive breast cancer obtained from the databases of HSK Wiesbaden and the breast center of Essen-Mitte hospital were evaluated. The observation period covered the years from 1998 to 2011. Follow-up data were collected both from the respective hospitals and from the data submitted annually by gynecologists in private practice linked to the intersectoral breast cancer quality assurance network for Wiesbaden and Essen. Patients with primary systemic recurrence or who underwent neoadjuvant chemotherapy were excluded from the study. Prior to beginning treatment, all patients gave their written consent to invasive procedures as well as to the prospective collection of their data.
Treatment recommendations
Postoperative systemic and radio-oncologic treatment was administered in accordance with national and international treatment recommendations accepted at the time (e.g. AGO treatment recommendations on breast cancer, S3-guideline on breast cancer, NCCN Guidelines for the treatment of breast cancer, St. Gallen Breast Cancer Conference consensus recommendations [26] [27] [28] [29] ). It should be noted that anti-HER2 monoclonal antibody therapy with trastuzumab was only available for systemic therapy after it had been approved for general use outside clinical trials in 2006. 5 % and 2 % of patients, respectively, rejected the recommendations to undergo chemotherapy or radiation therapy.
Classification into subgroups based on histopathological parameters
Approximate classification into intrinsic subgroups was done based on pathological parameters, with patients classified into one of the following 5 groups: 
Definition of study endpoints and statistical analysis
Incidence rates and associated prognostic parameters were calculated for local recurrence (LR) (defined as recurrence in residual breast tissue or thoracic wall), loco-regional recurrence (RR) (defined as recurrence in the ipsilateral lymph drainage area or axillary/infraclavicular/supraclavicular area) and systemic recurrence (DR) (defined as all other forms of recurrence) along with the corresponding 5-year disease-free survival rates which included local recurrence-free survival (LRFS), loco-regional recurrence-free survival (RRFS) and distant recurrence-free survival (DRFS). Statistical analysis was done using SPSS Statistics version 20.0. Survival period was defined as the period from the date of diagnosis to the development of recurrence or to the date of the last recorded clinical follow-up. All variables found on univariate analysis (p < 0.05) to affect survival were included in a multivariate model. Hazard ratios and 95% confidence intervals (95 % CI) were calculated and validated using the Cox proportional hazards model. Statistical significance was defined as p < 0.05 in two-sided test results.
Results
!
Patients and clinical-pathological parameters
A total of 3054 patients with primary diagnosis of early-stage invasive breast cancer were included in the analysis. Median follow-up was 6.6 years. A total of 380 (12.4 %) recurrences occurred during the follow-up period. Local or loco-regional recurrence occurred in 100 (3.3 %) and 32 (1%) of patients, respectively. Distant recurrence was recorded for 8 % (n = 245) of the patient population. 9 % (n = 289) of patients with primary breast cancer died without signs of recurrence. The 5-year disease-free survival rate was 88%. The clinical-pathological parameters are listed in l " Table 1.
On histopathological evaluation, 67 % (n = 2056) of tumors were classified as luminal A, 13% (n = 400) as luminal B (HER2−), 6 % (n = 185) as luminal B (HER2+), 3% (n = 92) as HER2+ and 11 % (n = 321) as TNBC (l " Table 1 ).
Local and systemic therapy and impact of anti-HER2 therapy
Breast-conserving surgery (BCS) was done in 68 % (n = 2081) of patients. The re-excision rate was 25 % (n = 762). Tumor-free margins were achieved postoperatively in 98% of cases. Axillary lymph node involvement was investigated in 97% of all patients (SNB: 33 %, ALND: 48 %, SNB followed by secondary ALND: 16 %). Local radiation oncology treatment was administered to 2306 (76 %) patients. 94% of patients had adjuvant systemic therapy (hormone treatment and/or chemotherapy and/or anti-HER2 therapy). 119 of 277 (43 %) patients with HER2-positive cancer received anti-HER2 therapy. Patients who had anti-HER2 therapy had a significantly higher 5-year RRFS (94 vs. 100%; p = 0.011) and distant recurrence-free survival (DRFS) (80 vs. 90 %; p = 0.011). However, LRFS did not differ significantly between both groups.
Risk factors for local recurrence
5-year and 10-year LRFS for the total patient population was 98 % and 94 %, respectively (l " Fig. 1 Table 2 ). On multivariate analysis, age ≤ 50 years, stage T3 tumor, positive node status, the subtypes luminal B (HER2−) and luminal B (HER2+), breast-conserving therapy and refusal of radiation therapy remained as independent negative risk factors (l " Table 3 ).
Risk factors for loco-regional recurrence 5-year and 10-year loco-regional recurrence-free survival (RRFS) was 99 % and 98% respectively (l " Fig. 1 ). There were significant differences in 5-year and 10-year RRFS in the intrinsic subgroups: subtype and refusal of radiation therapy remained independent negative prognostic factors (l " Table 3 ).
Risk factors for systemic recurrence
5-year and 10-year distant recurrence-free survival (DRFS) for this patient population was 92 % and 88 % respectively (l " Fig. 1) . However there were significant differences in 5-year and 10-year DRFS in the intrinsic subgroups: Fig. 2) . On univariate analysis stageT3/4 tumor, extensive nodal involvement (N2/3), negative hormone receptor status, positive HER2 status, high tumor grade, lymph node invasion, multifocality/multicentricity, type of surgery (mastectomy, as well as axillary lymph node dissection) and refusal of systemic and radio-oncologic therapy were found to be associated with a significantly higher risk of recurrence (l " Table 2) . On multivariate analysis, tumor size (> T1), node positivity, all subtypes (compared with reference type luminal A), evidence of lymph node involvement, type of surgery (mastectomy) and refusal of systemic and radiation therapy were independent negative risk factors (l " Table 3 ).
Comparison of recurrence risk between the intrinsic subgroups
On multivariate analysis, a significant increase of risk of local recurrence (LR) was found for the subgroups luminal B (HER2−) (HR: 2.4; 95 % CI: 1.4-4.1; p = 0.001) and TNBC (HR: 2.4; 95 % CI: 1.4-4.2; p = 0.001) compared to the luminal A tumor subgroup which served as reference (l " Table 3 ). For loco-regional recurrence (RR) the difference was only significant for the TNBC group (HR: 5.4; 95 % CI: 2.7-11; p = 0.001). All non-luminal A tumors were associated with a significantly higher risk of systemic recurrence (DR): luminal B (HER2−) (HR: 2.0; 95 % CI: 1.4-2.8; p < 0.001), luminal B (HER2+) (HR: 1.9; 95 % CI: 1.2-3.0; p = 0.007), HER2+ (HR: 2.4; 95% CI: 1.4-4.1; p = 0.001) and TNBC (HR: 2.2; 95 % CI 1.5-3.2; p = 0.001).
Comparison of risk factors LR, RR and DR
On multivariate analysis (l " Table 3 ) the following parameters were found to be associated with an increased risk for all types of recurrence (LR, RR, DR): nodal positivity, TNBC subgroup and refusal of radio-oncologic therapy. Status of the final margins and multifocality/multicentricity were not associated with increased risk. Age ≤ 50 was a prognostic factor for LR but not for RR or DR. Tumor size had a negative effect on LR and DR but was not found to affect RR. Signs of tumor invasion of the lymphatic vessels were associated with increased DR but not with increased LR or RR. Patients who had undergone mastectomy had a low risk 
Comparison of recurrence rates during the treatment period
To compare potential changes in recurrence rates we divided the observation period into 2 subperiods (1998-2005 and 2006-2011) . No significant differences in 5-year LRFS, RRFS and DRFS were found between the 2 subperiods. Discussion ! This study evaluated and compared the risk factors for local recurrence, loco-regional recurrence distant recurrence in 3054 patients with a primary diagnosis of early-stage, non-metastatic breast cancer treated in HSK Wiesbaden hospital and Essen-Mitte hospital. The risk of recurrence was analyzed for different subgroups. In our total patient population, the rates of local recurrence and loco-regional recurrence at 5 years after primary diagnosis were very low with rates of 3.3 and 1%, respectively. The rate of distant recurrence was 8 %. We showed that known risk factors such as age, nodal status, tumor size, lymphatic invasion in addition to undergoing systemic and radiation therapy affected recurrence rates in the different groups in varying ways. A continuous increase in the risk of LR, RR and DR (on multivariate analysis) was found for patients who had not undergone radiation therapy, with tumor stage >T2 or positive nodal status. Factors such as tumor-free margins and focality were not found to affect the risk of LR, RR and DR on multivariate analysis. The discussion about what constitutes the optimal margin for the prevention of local recurrence has been extremely controversial in recent years. After the initial requirement of a healthy resection margin of 5-10 mm in surgery for invasive carcinoma the current recommendation now proposes a healthy margin of 1 mm [28] .
In their current recommendations, the Society of Surgical Oncology and the American Society for Radiation Oncology have stated that no ink on the tumor margin is sufficient as an adequate margin in invasive cancer [30, 31] . This definition also aims to significantly reduce the rates of re-excision. In our patient population the rate of re-excision was 25 % which is comparable to that given in other international publications [32, 33] , even though an accompanying ductal carcinoma in situ (DCIS) was present in 48 % of our patients. Nevertheless, it can be reasonably assumed that the more restrictive definition of a tumor-free margin will lower the rate of re-excisions, particularly in view of the fact that approximately half of all re-excisions are done to extend an already existing healthy tumor-free margin [32, 33] . With regard to the risk of local recurrence for multifocal/multicentric (MF/MC) cancer, some of the data is controversial. In their study, Lynch et al. [34] reported no significant effect of focality on the risk of local recurrence compared to unifocal tumors and therefore concluded that breast-conserving therapy could be considered sufficiently safe in this patient cohort. However, in another study the authors showed that multicentricity but not multifocality was a negative prognostic factor with regard to the risk of systemic recurrence and overall breast-cancer-specific survival [35] . Other study groups [36, 37] have reported significantly better survival for patients with unifocal tumors compared with multifocal/multicentric tumors. In our study multifocality/ multicentricity did not constitute a risk factor for the investigated types of recurrence. The current German recommendations stipulate performing mastectomy in patients with multicentric tumors [28] . In our study, age ≤ 50 years was a risk factor for local recurrence (HR 2.1; 95% CI: 1.4-3.2) but not for loco-regional or systemic recurrence. Earlier studies published in the literature reported the 5-year LR risk for young women after BCS as ranging between 10 and 36 % [38] [39] [40] [41] . In their evaluation of 17 prospective studies, the EBCTCG (Early Breast Cancer Trialistsʼ Collaborative Group) showed that young women (< 40 years) after BCS had a significantly higher 10-year LR risk compared with older women (> 70 years) (36 vs. 9 %). This raises the question whether younger women with breast cancer should be advised against BCS. However, recent publications (and our own analysis) have reported a significantly lower 5-year LR risk of 5 % in young women [20] . Laar et al. [42] elegantly demonstrated the improvement in the LR rate over the period 1988-2010 in women < 40 years of age. Although the mean 5-year LR rate averaged over the entire period was 7.5 %, it differed quite considerably across the different observation periods: for the period 1988-1998 it was 9.8 %; for 1999-2005 it was 5.9 %; for 2005-2010 it was 3.3 % (p = 0.006). Because of the very low rates of recurrence in our patient population in the 2 observation periods, we found no significant differences between observation periods. Several studies which looked specifically at the safety of BCS in TNBC patients reported that these patients did not have an increased risk of LR if they underwent breast-conserving surgery [43, 44] . In the current St. Gallen recommendations published for 2013, BCS is not considered absolutely contraindicated in patients < 35 years [29] , nor do the first international consensus guidelines on the treatment of breast cancer in young women consider BCS to be contraindicated in young patients [45] . In our analysis, patients who had undergone mastectomy had a lower risk of LR; on the other hand they were found to be at higher risk of systemic recurrence. In our experience, patients with clearly advanced tumor stages and/or unfavorable tumor biology are more likely to have mastectomy procedures. However, surgery does not change the unfavorable tumor biology, meaning that while extensive surgery reduces the local risk of recurrence, it cannot change the risk of systemic recurrence.
Studies have shown that systemic therapy, whether it consists of anti-hormone therapy [46, 47] , chemotherapy and/or anti-HER2 therapy [48] , reduces the risk of recurrence. The findings in our study also demonstrated the impact of systemic therapy, in particular the impact of anti-HER2 therapy on patients with HER2positive cancer. These findings were in accord with those of previous studies [49, 50] . Patients with luminal-A tumors had excellent 5-year LRFS, RRFS and DRFS rates. In contrast, all patients with TNBC had a significantly higher risk of all forms of recurrence. 5-year DRFS was significantly lower in all subgroups compared to the luminal A tumor subgroup. In their meta-analysis of 12 592 patients, Lowery et al. [51] , showed that patients with TNBC or HER2+ subtypes had a significantly higher LR risk compared to patients with luminal/HER2− cancer, irrespective of the type of surgery (LR rate after BCS was 13.5 %; after mastectomy it was 12.9 %; mean follow-up: 57 months). We made the same observation in our study; however, the 5-year LR rate calculated in our analysis was significantly lower than in their study (TNBC and HER2+: 6% respectively). Pilewskie et al. [52] investigated the effect of resection margins after BCS on the risk for LR and DR in 535 TNBC patients.
Our study has some limitations which must be mentioned. It was a retrospective analysis of two German breast centers. Neither the surgical procedures nor the other therapies (radiation therapy, chemotherapy/antibody therapy/hormone therapy) were standardized; instead all treatment was carried out to the best of the knowledge at the time and in accordance with existing national/international recommendations. The exclusion of patients who had neoadjuvant treatment could have distorted the patient population as it could have led to a cumulation of more favorable tumor biologies. The data on the pathological parameters (especially the determination of receptors) was not collected centrally. However, our study gives an unfiltered picture of the daily treat-ment regimens in these hospitals without bias or selection. Our study is an important contribution to healthcare research into the verification of clinical standards, a field that is becoming increasingly important. Moreover, to the best of our knowledge, our study constitutes the biggest analysis of German data on this issue to date.
Conclusion
!
The LR and RR rates were very low in our patient population. The prognostic factors differed between investigated recurrence groups. Established risk factors such as age, nodal status and tumor size affected the different forms of recurrence to a varying extent. Based on the differentiation into subgroups, TNBC was associated with a significantly higher risk of local and loco-regional recurrence as well as a higher risk of systemic recurrence. The value of systemic therapy and radiation therapy was demonstrated by the significantly lower systemic recurrence rate in treated patients. In summary, the risk of recurrence must be evaluated on an individual basis and the treatment plan must consist of multimodal therapy which takes the individual tumor biology into consideration.
